Condition: Single Ventricle Heart Disease · Sponsor: Mezzion Pharma Co. Ltd
This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.
This description comes directly from the study's public registry record.
WG Kim · 443.699.6746 · wgkim@mezzion.com
Always discuss trial participation with your own doctor first.
| Phoenix Children's Hospital | Phoenix, Arizona, United States | Recruiting |
| Arkansas Children's | Little Rock, Arkansas, United States | Recruiting |
| Children's Hospital of Los Angeles | Los Angeles, California, United States | Recruiting |
| Rady Children's Hospital | San Diego, California, United States | Recruiting |
| UCSF Benioff Children's Hospital | San Francisco, California, United States | Recruiting |
| Children's Hospital of Colorado | Denver, Colorado, United States | Recruiting |
| Yale School of Medicine | New Haven, Connecticut, United States | Recruiting |
| Nemours Children's Hospital | Wilmington, Delaware, United States | Recruiting |
| Childrens National Medical Center | Washington D.C., District of Columbia, United States | Recruiting |
| UF Health Shands Hospital | Gainesville, Florida, United States | Recruiting |
| Joe DiMaggio Children's Hospital | Hollywood, Florida, United States | Recruiting |
| Johns Hopkins All Children's Hospital | St. Petersburg, Florida, United States | Recruiting |
+ 28 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05918211